Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG. Sauta E, et al. J Clin Oncol. 2023 May 20;41(15):2827-2842. doi: 10.1200/JCO.22.01784. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930857 Free PMC article.
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, Caballero-Berrocal JC, Ortega R, Redondo AM, Sánchez-Guijo F, Muntión S, García-Martín L, Albarrán B, Alonso JM, Del Cañizo C, Hernández-Hernández Á, Díez-Campelo M. Jiménez-Solas T, et al. Br J Haematol. 2019 Oct;187(1):93-104. doi: 10.1111/bjh.16013. Epub 2019 Jun 6. Br J Haematol. 2019. PMID: 31172513 Free article. Clinical Trial.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G. Germing U, et al. Ann Hematol. 2023 Feb;102(2):311-321. doi: 10.1007/s00277-022-05071-8. Epub 2023 Jan 13. Ann Hematol. 2023. PMID: 36635381 Free PMC article. Clinical Trial.
Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology.
D'Amico S, Dall'Olio D, Sala C, Dall'Olio L, Sauta E, Zampini M, Asti G, Lanino L, Maggioni G, Campagna A, Ubezio M, Russo A, Bicchieri ME, Riva E, Tentori CA, Travaglino E, Morandini P, Savevski V, Santoro A, Prada-Luengo I, Krogh A, Santini V, Kordasti S, Platzbecker U, Diez-Campelo M, Fenaux P, Haferlach T, Castellani G, Della Porta MG. D'Amico S, et al. JCO Clin Cancer Inform. 2023 Jun;7:e2300021. doi: 10.1200/CCI.23.00021. JCO Clin Cancer Inform. 2023. PMID: 37390377 Free article.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: diez campelo m. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI, Ribate VE, Muñoz CM, Santillana SG, Taboada SE, Casterá ME, Abinzano CMJ, Barranco IA, Nieto CR, Pampliega VM, Blanco ML, de Andrés ÁS, de Oteyza PJ, Del Castillo BT, Font GI, Cayuela JA, Díez-Campelo M, Sánchez AR, Vercet SC, Díaz TM; Grupo Español de Síndromes Mielodisplásicos (GESMD). Castillo MI, et al. Cancer Med. 2023 Aug;12(16):16788-16792. doi: 10.1002/cam4.6300. Epub 2023 Jul 5. Cancer Med. 2023. PMID: 37403747 Free PMC article.
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells.
Navarro-Bailón A, López-Parra M, Veiga-Vaz Á, Villarón EM, Díez-Campelo M, Martín AÁ, Pérez-López E, Cabrero M, Vázquez L, López-Corral L, Sánchez-Guijo F. Navarro-Bailón A, et al. Among authors: diez campelo m. Cytotherapy. 2024 Apr 21:S1465-3249(24)00612-1. doi: 10.1016/j.jcyt.2024.04.006. Online ahead of print. Cytotherapy. 2024. PMID: 38727653
Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
Gregorio C, Spreafico M, D'Amico S, Sauta E, Asti G, Lanino L, Tentori CA, Platzbecker U, Haferlach T, Diez-Campelo M, Fenaux P, Komrokji R, Della Porta MG, Ieva F. Gregorio C, et al. Among authors: diez campelo m. JCO Clin Cancer Inform. 2024 May;8:e2300205. doi: 10.1200/CCI.23.00205. JCO Clin Cancer Inform. 2024. PMID: 38723213 Free article.
115 results